Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential therapeutic targets in ARID1A-mutated cancers.

Expert opinion on therapeutic targets - 1 Jan 2015

Bitler Benjamin G, Fatkhutdinov Nail, Zhang Rugang

Abstract excerpt

ARID1A is a subunit of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex that regulates gene expression by controlling gene accessibility. ARID1A shows one of the highest mutation rates across different human cancer types. For example, ARID1A is mutated in ∼ 50% of ovarian clear cell carcinoma (OCCC). There is considerable interest in developing cancer therapeutics that correlate with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA-Binding Proteins
Share to Gene Expression Regulation, Neoplastic
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Nuclear Proteins

Share to Ovarian Neoplasms

Share to Transcription Factors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 26125128
DOI: 10.1517/14728222.2015.1062879
PMCID: PMC4674066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential therapeutic targets in ARID1A-mutated cancers.PMID 26125128Read ↗

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient MalignanciesSemantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.Semantic proximity Read ↗

The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis.Semantic proximity Read ↗

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.Semantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

ARID1A mutations in cancer development: mechanism and therapy.Semantic proximity Read ↗

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?Semantic proximity Read ↗

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage responseSemantic proximity Read ↗

Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant SubtypesSemantic proximity Read ↗

The effects of ARID1A mutation in gastric cancer and its significance for treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.